Jason A Efstathiou
Overview
Explore the profile of Jason A Efstathiou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
6287
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury D, Apolo A, Jiang D, Skinner E, Chisolm S, Bangs R, et al.
BJU Int
. 2025 Mar;
PMID: 40047292
Objectives: To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for...
2.
Apolo A, Baumann B, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251319185.
PMID: 40034245
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led...
3.
Kotha N, Kumar A, Riviere P, Nelson T, Qiao E, Salmasi A, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102229.
PMID: 39709685
Background: Real-world outcomes, especially patterns of failure, are limited for patients with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy (TMT). We aim to evaluate patterns of failure after TMT...
4.
Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens
Flannery B, Sandler H, Lal P, Feldman M, Santa-Rosario J, Pathak T, et al.
J Pathol
. 2024 Dec;
265(2):146-157.
PMID: 39660731
The presence, location, and extent of prostate cancer is assessed by pathologists using H&E-stained tissue slides. Machine learning approaches can accomplish these tasks for both biopsies and radical prostatectomies. Deep...
5.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
6.
Patel K, Nguyen P, Proudfoot J, Liu Y, Dal Pra A, Spratt D, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39542826
Background And Objective: Long-term (LT) androgen deprivation therapy (ADT) has been found to be beneficial to patients with high-risk prostate cancer (PCa). However, administration of LT-ADT to all patients with...
7.
Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, et al.
Bladder Cancer
. 2024 Nov;
10(3):199-213.
PMID: 39493817
Background: Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therapeutics in different...
8.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
9.
Wisdom A, Yeap B, Michalski J, Horick N, Zietman A, Christodouleas J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Oct;
121(3):741-751.
PMID: 39357788
Purpose: Men with localized prostate cancer may receive either photon-based intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT). The PARTIQoL trial (NCT01617161) demonstrates the feasibility of performing a...
10.
Baumann B, Efstathiou J
Int J Radiat Oncol Biol Phys
. 2024 Oct;
121(3):737-740.
PMID: 39353476
No abstract available.